Stay updated with breaking news from Ianm Mcelree. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For patients with non-muscle invasive bladder cancer (NMIBC), gemcitabine and docetaxel therapy is associated with less high-grade disease recurrence.
Less high-grade NMIBC disease recurrence and lower treatment discontinuation seen with gemcitabine and docetaxel vs bacillus Calmette-Guérin.
The chemotherapy duo performed better than expected as a stand-in for bacillus Calmette-Guérin (BCG), which is the gold standard for non–muscle-invasive bladder cancer but is currently in short supply.
Gemcitabine plus docetaxel (Gem/Doce) may be an alternative for the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC).
Gemcitabine plus docetaxel may be an alternative for the treatment of high-risk non-muscle-invasive bladder cancer.